Early clinical research
ELI-002 — amphiphile peptide vaccine in KRAS-mutant solid tumors (phase I)
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors
- Phase
- Phase I
- Recruitment
- Completed
- Results maturity
- Interim analysis
- Publication
- Peer-reviewed
- Regulatory approval
- No regulatory approval
- NCT
- NCT04853017
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? An off-the-shelf (not personalized) peptide vaccine stimulating immunity was tested early in KRAS-mutated tumors. It is not an mRNA vaccine.
Why promising? Measures safety and immune response of an off-the-shelf KRAS-targeted peptide vaccine in early clinic.
What is not proven? Survival superiority; phase III; same class as mRNA vaccines or superiority vs autogene.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
AMPLIFY-201 / NCT04853017 phase I completed. Amphiphile peptide + CpG; not mRNA or personalized neoantigen vaccine. Nature Medicine 2024 context; no phase III yet.
Cancer / population: Pancreas, Multiple / solid tumors — KRAS mutant PDAC ve diğer solid tümörler (protokol; AMPLIFY-201)
Intervention: ELI-002 (amphiphile KRAS peptid + CpG adjuvant aşı; kişiye özel mRNA değildir)
Primary endpoint: Güvenlik / immünojenisite
Limitations: Erken faz; etkinlik iddiası sınırlı; mRNA aşı kartlarıyla karıştırılmaz.